Sign in
CompletedPhase 1

To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects

Key facts

Who runs it
Jiaxing AnDiCon Biotech Co.,Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
16 people enrolled
Started
14 Mar 2024
Ended
21 Jun 2024
Type of study
Interventional, 4 groups
Treatments tested
  • ADC189
Record updated
20 January 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • 1) The subjects fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign a written informed consent, and can complete the entire trial process according to the requirements of the trial
  • 2) Age 18-75 years old (including the boundary value), both male and female
  • 3) The body weight of male subjects was ≥50 kg, the body weight of female subjects was ≥45 kg, and the body mass index (BMI) was within the range of 18.0~30.0 kg/m²

Who cannot take part

  • 3) Patients with severe infection, trauma, gastrointestinal surgery or other major surgical operations within 4 weeks before screening
  • 1) Known allergic history to test drug components, or allergic constitution, or history of allergic diseases
  • 2) Have malignant tumors, or have a history of malignant tumors within 5 years prior to screening
  • 4) eGFR (CKD-EPI Cr) <60mL/min/1.73m2

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of ADC189 in subjects with hepatic impairment compared with subjects with normal hepatic function.

The 4 groups in the trial

  • ADC189 to Child-Pugh Class ATreatment being tested

    Subjects with Child-Pugh Class A received a single dose once of ADC189 (45 mg/1 tablet).

    Treatment: ADC189

  • ADC189 to normal haptic function (A)Treatment being tested

    Healthy subjects who marched with Group "Child-Pugh Class A", that received a single dose of ADC189 (45 mg/1 tablet).

    Treatment: ADC189

  • ADC189 to Child-Pugh Class BTreatment being tested

    Subjects with Child-Pugh Class B received a single dose once of ADC189 (45 mg/1 tablet).

    Treatment: ADC189

  • ADC189 to normal haptic function (B)Treatment being tested

    Healthy subjects who marched with Group "Child-Pugh Class B", that received a single dose of ADC189 (45 mg/1 tablet).

    Treatment: ADC189

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Phase I, Open-label, Multi-center, Parallel, Single Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ADC189 in Subjects With Hepatic Impairment (Child-Pugh A and B) Compared With Subjects With Normal Hepatic Function
Record updated
20 January 2025